Item 5.02 - Board Expansion and Director Appointment: The Board of Directors increased from ten to eleven members and appointed Robert Plenge, M.D., Ph.D. as a new director, effective September 10, 2026 Committee Assignment: Dr. Plenge was appointed to the Science and Technology Committee of the Board Director Compensation: Dr. Plenge will receive standard director fees as an independent…

Our analysis rates this filing BULLISH. This 8-K filing documents a standard board composition change with no material concerns. Dr. Robert Plenge's appointment as an independent director with placement on the Science and Technology Committee represents routine board management for a pharmaceutical…

Concern level: LOW (1.5/10).

Notable risk changes: Board expansion: Size increased from 10 to 11 members with appointment of Dr. Robert Plenge, M.D., Ph.D.; Dr. Plenge granted $400,000 in restricted stock units (RSUs) as pro-rata 2026 director compensation; Dr. Plenge appointed to Science and Technology Committee, vesting upon next annual stockholder meeting.